drugset
drugset / Trial / NCT02518802

Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma

NCT02518802 ↗

Phase 3 Unknown 220 enrolled Tang-Du Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized phase III trial is studying gefitinib and synchronous pemetrexed/cisplatin chenmotherapy to see how well it works compared to pemetrexed/cisplatin chenmotherapy alone in treating patients who have undergone surgery for stage II-IIIA(N1-N2) lung adenocarcinoma with EGFR activating mutation in Asian population.

Timeline

Start
2015-01
Primary completion
2018-01
Completion
2020-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefitinib Small molecule 250 mg Oral
Background Cisplatin Other / unclassified 75 mg/m2 —
Background Pemetrexed Small molecule 500 mg/m2 —

Indications

lung neoplasm